Clinical Trials Logo

Cancer, Rectum clinical trials

View clinical trials related to Cancer, Rectum.

Filter by:
  • None
  • Page 1

NCT ID: NCT05667259 Completed - Cancer, Rectum Clinical Trials

Prognostic Significance of Lymph Node Ratio in Rectal Cancer on Overall Survival

Start date: January 1, 2012
Phase:
Study type: Observational

This study was conducted to compare the significance of lymph node ratio and absolute count of positive lymph node count on overall survival in patients with rectal cancer who underwent resection with curative intent

NCT ID: NCT05646043 Recruiting - Cancer, Rectum Clinical Trials

PREHAB - Improving Condition Before Surgery

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

The pilot research project is focused on the feasibility of a prehabilitation program for two groups of diagnoses (esophageal and stomach cancer, rectal cancer).

NCT ID: NCT05154474 Not yet recruiting - Metastatic Cancer Clinical Trials

Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy

SPACE2
Start date: June 2022
Phase:
Study type: Observational

Sarcopenia is defined as reduction in muscle mass and function according to the criteria of the European Working Group on Sarcopenia in older people. Initially described for elderly patients, it is also presented as a negative prognostic factor in overall survival in oncology in certain locations (lung, ENT pathways, colon, pancreas) and more controversially for hemopathies. Its screening by measurement of skeletal muscle mass by CT scan and / or PET scan against L3 and by physical functional tests is not routinely integrated despite international recommendations. Sarcopenia is one of the characteristics of patient fragility that can induce more complications, lengthen the average length of hospital stay and reduce overall survival. The PRONOPALL score, a predictor score for survival validated by a previous study, will be correlated with the presence (or absence) of sarcopenia at inclusion for patients with a solid tumor (breast, ovary, prostate cancer , kidney, lungs, pancreas, colorectal). A prospective study on 38 patients with metastatic cancer was carried out at the Victor Hugo clinic in Le Mans between 01/JUN/21 and 31/AUG/21 (SPACE, ClinicalTrials.gov number, NCT04714203): 25 patients were analyzable on the CT and PRONOPALL score data with a prevalence of sarcopenia of 60% and median overall survival of 14 months (unpublished data), clinical performance and muscle strength tests were not carried out (as in the publications cited above). A prospective study for the detection of sarcopenia is indicated by extending to blood diseases with the integration of clinical tests included in the initial APA (Adapted physical activity) assessment recommended for diagnosis.

NCT ID: NCT04790227 Not yet recruiting - Cancer, Rectum Clinical Trials

MRI for Selection of Complete Responders After Chemoradiation for Locally Advanced Rectal Cancer

Start date: January 2022
Phase:
Study type: Observational

The purpose of our study is to evaluate the accuracy of MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer .

NCT ID: NCT04401787 Completed - Cancer, Rectum Clinical Trials

Converted Laparoscopic Resection of Upper Rectal Carcinoma T1-4 N0-1 in Obese Patients.

Start date: December 11, 2016
Phase: N/A
Study type: Interventional

Background: laparoscopic resection (LAR) is a safe approach and widely used for rectal cancer after neoadjuvant chemo-radiotherapy, but short term and oncological outcome for converted cases to open surgery (cLAR), may be questioned in an obese patient. Objective: validating the short-term and oncological outcomes after laparoscopic resection and after conversion to open surgery for upper rectal cancer in obese patients. Patients and methods: A prospective study included 191 patients, randomly allocated into two arms of the study, Arm I is open anterior resection (OAR), this is the control and arm II, The LAR. Only 156 analyzed.

NCT ID: NCT03688906 Completed - Colo-rectal Cancer Clinical Trials

AI-EMERGE: Development and Validation of a Multi-analyte, Blood-based Colorectal Cancer Screening Test

Start date: January 12, 2018
Phase:
Study type: Observational [Patient Registry]

Freenome is using a type of artificial intelligence, called machine learning, to identify patterns of cell-free biomarkers in blood to detect cancer early. The purpose of this study is to develop and validate a blood-based assay to detect colorectal cancer by collecting blood and stool samples from healthy patients undergoing routine screening colonoscopy and from patients recently diagnosed with colorectal cancer or advanced adenomas.

NCT ID: NCT03628248 Completed - Cancer, Rectum Clinical Trials

Effect of Endovascular Inferior Mesenteric Artery Embolization on Colonic Perfusion Prior to Rectal Surgery for Rectal Tumor or Sigmoid Colon Surgery

AMIREMBOL
Start date: March 10, 2020
Phase: N/A
Study type: Interventional

The investigators hypothesize that a primary embolization, 3-4 weeks before surgery, would allow development of vascular collaterality, in particular for the marginal artery which will ensure a better colonic perfusion.

NCT ID: NCT02533271 Recruiting - Cancer, Rectum Clinical Trials

Optimization of Preoperative Treatment in Locally Advanced Rectal Cancer

STELLAR
Start date: August 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare effectiveness of short-term radiotherapy with neoadjuvant chemotherapy(TNT group) with preoperative long-term chemoradiotherapy(CRT group) in locally advanced rectal cancer. The hypothesis is 3-year disease-free survival in TNT group was non-inferior to that in CRT group.